Press Releases

REDWOOD CITY, CA – September 21, 2016 – PaxVax today announced its President and CEO, Nima Farzan, has been invited to join the interim board of the Coalition for Epidemic Preparedness Innovations (CEPI) as the Biotechnology Innovation Organization (BIO) delegate. CEPI is a new, public-private alliance designed to speed the development of new vaccines to prevent and contain global epidemics. Sparked by recent gaps in vaccine preparedness for outbreaks of Zika and Ebola, CEPI aims to facilitate the creation of an arsenal of vaccines to prevent diseases such as these from becoming public health emergencies in the future.

“PaxVax is committed to developing and delivering vaccines that address global public health threats. In joining the CEPI leadership, I look forward to continue pursuing innovative efforts aimed to prepare against future pandemics,” said Farzan. “As biotech companies have both the expertise and responsibility to take part in this cause, I am thrilled to join CEPI’s visionary team of experts in the global fight to protect against infectious diseases.”

CEPI was founded by the Wellcome Trust, the Bill and Melinda Gates Foundation, the World Economic Forum and the governments of Norway and India. The organization will finance, coordinate and facilitate the development of vaccines for potential global threats before outbreaks begin. Farzan joins CEPI’s board of global leaders from academia, government, non-profits and industry, gathered to shape an informed, collaborative approach to ensure vaccines are available for all populations who need them.

 

“We have seen in recent outbreaks that when working alone, industry players face barriers to vaccine development,” Farzan said. “CEPI’s collaborative approach is vital in taking on global health threats. I am proud to serve on its board among leaders forging a unified response to pandemics.”

Farzan has been President and CEO of PaxVax since 2015 and previously served as Chief Operating Officer from 2011. He has extensive biopharmaceutical experience, most recently providing leadership at PaxVax in the advancement of a vaccine for cholera from research and development through to approval by the U.S. Food and Drug Administration.

About PaxVax

PaxVax develops, manufactures and commercializes innovative specialty vaccines against infectious diseases present and emerging in the developing world. PaxVax has licensed vaccines for typhoid fever (Vivotif®) and cholera (Vaxchora), and vaccines at various stages of research and clinical development for adenovirus, anthrax, hepatitis A, HIV, and Zika. PaxVax is focused on traditionally overlooked markets such as travel, and as part of its social mission, PaxVax is also working to make its vaccines available to broader populations most affected by these diseases. PaxVax is headquartered in Redwood City, California and maintains research and development and Good Manufacturing Practice (GMP) facilities in San Diego, California and Bern, Switzerland and other operations in Bermuda and Europe. More information is available at www.PaxVax.com.

Contact

David Polk

Biosector 2

310-309-1029

 

David.Polk@inventivhealth.com 

PaxVax Named Best Early-Stage Company at Vaccine Industry Excellence (ViE) Awards

Washington, D.C. and Redwood City, Calif. – March 30, 2016 – PaxVax Inc., a fully integrated specialty vaccine company committed to developing and commercializing innovative vaccines against infectious diseases, today announced that it was named Best Early-Stage Vaccine Biotech company at the 9th annual Vaccine Industry Excellence (ViE) Awards. Winners were announced at a ceremony held during the 16th annual World Vaccine Congress taking place in Washington, D.C., March 29-31. 

PaxVax Appoints Nima Farzan Chief Executive Officer

REDWOOD CITY, Calif. -- May 11, 2015 -- PaxVax, Inc., a specialty vaccine company focused on travel and biodefense, today announced that the Board of Directors has appointed Nima Farzan Chief Executive Officer and President. In this role, he will assume overall responsibility for PaxVax, including management of all R&D, manufacturing and commercial operations globally.

PaxVax Announces Global Expansion of Commercial Network for its Typhoid Vaccine Vivotif

REDWOOD CITY, California – April, 22 2015 – PaxVax, Inc., a specialty vaccine company focused on travel and biodefense, today announced a series of new commercial partnerships and distribution agreements for its commercial typhoid vaccine Vivotif®. These agreements will ensure the global availability of Vivotif across Europe and Australia and complement the company’s growing direct sales and marketing capabilities in the United States.

PaxVax to Present at 33rd Annual J.P. Morgan Healthcare Conference

REDWOOD CITY, Calif. – January 8, 2015 – PaxVax, Inc., a specialty vaccine company focused on travel and biodefense, today announced that Chief Executive Officer Kenneth Kelley will present at the annual J.P. Morgan Healthcare Conference in San Francisco on Tuesday, January 13, at 5:00 p.m. Pacific Standard Time.

PaxVax Announces Primary Endpoints Met in Phase 3 Cholera Vaccine Trial

Positive Lot-to-Lot Consistency Data Pave Way for Biologics License Application (BLA) Submission in 2015.

REDWOOD CITY, Calif. – December 8, 2014 – PaxVax Inc., a specialty vaccine company focused on travel and biodefense, today announced positive results from a Phase 3 safety and lot-to-lot consistency trial of its single-dose oral cholera vaccine candidate, PXVX0200, which utilizes the same attenuated vaccine strain (CVD 103-HgR) previously approved and marketed in several countries under the brand name Orochol®. PaxVax intends to submit a Biologics License Application (BLA) for this product, under the brand name Vaxchora®, to the U.S. Food and Drug Administration (FDA) in mid-2015.

Specialty Vaccine Company PaxVax Expands Global Commercial Team

REDWOOD CITY, CALIF. – August 7, 2014 -- PaxVax, Inc., a specialty vaccine company focused on travel and biodefense, today announced the expansion of its global commercial team with the appointments of Jonathan Klock as Vice President of Sales and Marketing, North America; Jeremy Gowler as Vice President of Global Marketing; and five U.S. National Account Directors. They join the European and U.S.-based commercial teams who came to PaxVax in conjunction with the company’s acquisition of the oral typhoid vaccine Vivotif ® last month.

Pages